文献速递银屑病与炎症性皮肤病自身免疫性与大疱性皮肤病

阿达木单抗治疗银屑病诱发矛盾性溃疡性结肠炎:换用乌司奴单抗后缓解

Paradoxical ulcerative colitis during adalimumab treatment of psoriasis resolved by switch to ustekinumab.
PubMed 文献 · Br J Dermatol · 2017-11-28

本文报告一例银屑病患者在使用阿达木单抗后出现溃疡性结肠炎,停用阿达木单抗后结肠炎显著改善,但银屑病加重,换用乌司奴单抗后结肠炎完全停止,随访2年无胃肠道症状。作者提出「矛盾性溃疡性结肠炎」这一术语,并认为这是首例银屑病患者使用阿达木单抗后出现该现象的报道。

要点

  • 阿达木单抗治疗银屑病可能诱发矛盾性溃疡性结肠炎。
  • 停用阿达木单抗后结肠炎改善,但银屑病可能加重。
  • 换用乌司奴单抗可同时控制结肠炎和银屑病。

核心结论

  • 阿达木单抗治疗银屑病可能诱发矛盾性溃疡性结肠炎,换用乌司奴单抗后结肠炎完全缓解且银屑病得到控制。

研究设计与样本

  • 个案报道,描述一例银屑病患者在阿达木单抗治疗期间出现溃疡性结肠炎,停药后换用乌司奴单抗并随访2年。

主要发现

  • 停用阿达木单抗后结肠炎显著改善,但银屑病加重。
  • 换用乌司奴单抗后结肠炎完全停止,2年随访期间无胃肠道症状复发。

临床怎么用

  • 对阿达木单抗治疗中出现胃肠道症状的银屑病患者,应警惕矛盾性溃疡性结肠炎的可能。
  • 乌司奴单抗可作为抗TNF抑制剂诱发的矛盾性炎症反应(如银屑病或IBD)的有效治疗选择。

局限性

  • 本文为单例个案报道,证据级别有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Here we report the case of a patient with psoriasis who developed ulcerative colitis most likely caused by adalimumab. After cessation of adalimumab, colitis improved significantly. However, as psoriasis worsened, the patient was switched to ustekinumab, which resulted in complete cessation of colitis. During the 2-year follow-up under ustekinumab therapy, no further gastrointestinal complaints occurred. Paradoxical psoriasis manifestations in inflammatory bowel disease (IBD) under tumour necrosis factor (TNF)-inhibitor therapy have been reported and paradoxical IBD occurred rarely (mostly Crohn disease) in patients with rheumatological conditions treated with infliximab or etanercept. Due to the highly probable association of adalimumab with the onset of colitis in this case, we would like to suggest the term 'paradoxical ulcerative colitis' (PUC) for this as yet extremely rarely reported phenomenon. To the best of our knowledge this is the first description of PUC in a patient with psoriasis and in adalimumab treatment. Our observation suggests that ustekinumab is an effective treatment option in patients with paradoxical anti-TNF-driven inflammatory reactions like psoriasis or IBD.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Kolios AGA, Biedermann L, Weber A, et al. Paradoxical ulcerative colitis during adalimumab treatment of psoriasis resolved by switch to ustekinumab. Br J Dermatol. 2017. PMID: 28477389. doi:10.1111/bjd.15631

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。